2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trialIan Smith, Martine Piccart, Marion Procter et al.|The Lancet|2007Cited by 1.5k
Supplement from Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast CancerIoannis Vathiotis, David L. Rimm, Myrto Moutafi et al.|Unknown|2023Cited by 0
Figure S1 from Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast CancerIoannis Vathiotis, David L. Rimm, Myrto Moutafi et al.|Unknown|2023Cited by 0
Figure S4 from Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast CancerIoannis Vathiotis, David L. Rimm, Myrto Moutafi et al.|Unknown|2023Cited by 0
Figure S2 from Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast CancerIoannis Vathiotis, David L. Rimm, Myrto Moutafi et al.|Unknown|2023Cited by 0